149 related articles for article (PubMed ID: 19257852)
1. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
Morrison J; Briggs SS; Green NK; Thoma C; Fisher KD; Kehoe S; Seymour LW
Hum Gene Ther; 2009 Mar; 20(3):239-51. PubMed ID: 19257852
[TBL] [Abstract][Full Text] [Related]
2. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
Morrison J; Briggs SS; Green N; Fisher K; Subr V; Ulbrich K; Kehoe S; Seymour LW
Mol Ther; 2008 Feb; 16(2):244-51. PubMed ID: 18071336
[TBL] [Abstract][Full Text] [Related]
3. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
Green NK; Morrison J; Hale S; Briggs SS; Stevenson M; Subr V; Ulbrich K; Chandler L; Mautner V; Seymour LW; Fisher KD
J Gene Med; 2008 Mar; 10(3):280-9. PubMed ID: 18214996
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Uusi-Kerttula H; Legut M; Davies J; Jones R; Hudson E; Hanna L; Stanton RJ; Chester JD; Parker AL
Hum Gene Ther; 2015 May; 26(5):320-9. PubMed ID: 25919378
[TBL] [Abstract][Full Text] [Related]
5. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
Tsuruta Y; Pereboeva L; Glasgow JN; Rein DT; Kawakami Y; Alvarez RD; Rocconi RP; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2007 May; 13(9):2777-83. PubMed ID: 17473211
[TBL] [Abstract][Full Text] [Related]
6. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.
Blackwell JL; Miller CR; Douglas JT; Li H; Reynolds PN; Carroll WR; Peters GE; Strong TV; Curiel DT
Arch Otolaryngol Head Neck Surg; 1999 Aug; 125(8):856-63. PubMed ID: 10448731
[TBL] [Abstract][Full Text] [Related]
7. Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor.
Wienen F; Nilson R; Allmendinger E; Graumann D; Fiedler E; Bosse-Doenecke E; Kochanek S; Krutzke L
Biomater Adv; 2023 Jan; 144():213208. PubMed ID: 36442453
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.
Pereboeva L; Komarova S; Roth J; Ponnazhagan S; Curiel DT
Gene Ther; 2007 Apr; 14(8):627-37. PubMed ID: 17251987
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.
Yoon AR; Kasala D; Li Y; Hong J; Lee W; Jung SJ; Yun CO
J Control Release; 2016 Jun; 231():2-16. PubMed ID: 26951927
[TBL] [Abstract][Full Text] [Related]
11. Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma.
Leath CA; Kataram M; Bhagavatula P; Gopalkrishnan RV; Dent P; Fisher PB; Pereboev A; Carey D; Lebedeva IV; Haisma HJ; Alvarez RD; Curiel DT; Mahasreshti PJ
Gynecol Oncol; 2004 Aug; 94(2):352-62. PubMed ID: 15297172
[TBL] [Abstract][Full Text] [Related]
12. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.
Harvey TJ; Burdon D; Steele L; Ingram N; Hall GD; Selby PJ; Vile RG; Cooper PA; Shnyder SD; Chester JD
Gene Ther; 2010 Aug; 17(8):1000-10. PubMed ID: 20410926
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
15. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
16. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
17. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.
Fisher KD; Stallwood Y; Green NK; Ulbrich K; Mautner V; Seymour LW
Gene Ther; 2001 Mar; 8(5):341-8. PubMed ID: 11313809
[TBL] [Abstract][Full Text] [Related]
18. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
19. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
20. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
